ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Cholecystokinin 2 Receptor AgonistJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Synthesis and in vitro evaluation of pharmacokinetically optimizedEJNMMI radiopharmacy and chemistry · 2026Article
- Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.European journal of nuclear medicine and molecular imaging · 2026Review
- Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [Pharmaceutics · 2026Article
- Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.Cancer communications (London, England) · 2025Review
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Radiopharmaceutical formulation and preliminary clinical dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Unnatural Amino Acids: Strategies, Designs, and Applications in Medicinal Chemistry and Drug Discovery.Journal of medicinal chemistry · 2024Review
- Comparison of Two Chelator Scaffolds as Basis for Cholecystokinin-2 Receptor Targeting Bimodal Imaging Probes.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2024Review
- Cholecystokinin-2 receptor targeting by [European journal of nuclear medicine and molecular imaging · 2024Article
- Advances in Radioligand Theranostics in Oncology.Molecular diagnosis & therapy · 2024Review
- Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.EJNMMI research · 2024Article
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Precision peptide theranostics: developingTheranostics · 2024Article
- Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.EJNMMI research · 2023Article
- Development of the FirstPharmaceutics · 2023Article
- Effect ofPharmaceutics · 2023Article
- Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Molecular imaging and targeted radiotherapy with radiolabeled cholecystokinin-2 receptor (CCK2R) targeting peptide probes holds high promise to improve the clinical management of patients with metastatic medullary thyroid carcinoma and other CCK2R-expressing malignancies. Low stability and suboptimal targeting of currently available radiolabeled peptide analogs has prompted us to seek new stabilization strategies. In this study, we present a new minigastrin analog with site-specific C-terminal modifications showing a highly optimized targeting profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.